Shweta Joshi

发表

Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient Mice

D. Durden, V. Bhat, A. Drygalski, 2018, Thrombosis and Haemostasis.

A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis

D. Durden, Shweta Joshi, A. Singh, 2014, Molecular Cancer Research.

MDM2 Regulates Hypoxic Hypoxia-inducible Factor 1α Stability in an E3 Ligase, Proteasome, and PTEN-Phosphatidylinositol 3-Kinase-AKT-dependent Manner*

D. Durden, Shweta Joshi, A. Singh, 2014, The Journal of Biological Chemistry.

Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication

S. Spector, D. Durden, G. Campbell, 2018, The Journal of Biological Chemistry.

De novo mutations in fetal brain specific enhancers play a significant role in severe intellectual disability

D. Fitzpatrick, Inês Cebola, Matías G De Vas, 2019 .

“Re-educating” Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma

Kevin X. Liu, Shweta Joshi, 2020, Frontiers in Immunology.

SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer

C. Glass, D. Durden, J. Garlich, 2019, Molecular Cancer Therapeutics.

Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in 12 V-Ha-Ras transgenic mouse glioma model

D. Durden, Shweta Joshi, A. Singh, 2014, Cancer Cell International.

Novel Therapeutic Approaches for Neuroblastoma

D. Durden, Shweta Joshi, A. Singh, 2013 .

Single Agent and Synergistic Activity of the “First-in-Class” Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma

J. Sicklick, S. Ikeda, Y. Kono, 2016, Molecular Cancer Therapeutics.

PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment.

D. Durden, Shweta Joshi, A. Singh, 2014, Experimental cell research.

Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.

P. Laird, M. Campan, W. Ye, 2017, Oncotarget.

A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity

D. Durden, T. Kutateladze, Francisco M. Vega, 2020, Cell Discovery.

Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype

D. Durden, M. Selman, A. Pardo, 2017, PloS one.

Sleep Disorder in Children Suﬀering from Autism Spectrum Disorder in the Hilly Area of Uttarakhand

S. Ojha, Shweta Joshi, Ashok Kumar, 2020, Asian Journal of Clinical Pediatrics and Neonatology.

Vascular remodeling underlies rebleeding in hemophilic arthropathy

J. Luck, T. Hughes, D. Durden, 2015, American journal of hematology.

Vascular Remodeling Underlies Re-Bleeding in Hemophilic Arthropathy

J. Luck, T. Hughes, D. Durden, 2015 .

ETIOLOGY OF SUPPURATIVE CORNEAL ULCERS IN RURAL POPULATION OF NORTHERN INDIA

A. Tandon, S. Ojha, Neeraj K. Saraswat, 2015 .

Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy

A. Sharabi, Shweta Joshi, 2022, Pharmacology & therapeutics.

Perioperative Challenges in the Management of Rhino-Orbital Cerebral Mucormycosis: An Observational Study from a Tertiary Care Hospital

Shweta Joshi, P. Bhalerao, Shital Kuttarmare, 2022, Anesthesia, essays and researches.

Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma

D. Durden, Shweta Joshi, A. Singh, 2015, Cancer Chemotherapy and Pharmacology.

Anesthesia Concerns in the Management of Low Birth Weight Neonate for Giant Sacrococcygeal Teratoma Excision: Case Series of Two Cases

Shweta Joshi, Madhu Chavan, 2020 .

Pediatric Phase II Trials of Poly-ICLC in the Management of Newly Diagnosed and Recurrent Brain Tumors

T. MacDonald, S. Vandenberg, D. Durden, 2014, Journal of pediatric hematology/oncology.

Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma.

Ashutosh Kumar Singh, D. Durden, Shweta Joshi, 2021, Journal of pediatric hematology/oncology.

PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma

Yoon-Jae Cho, M. Levy, D. Durden, 2016, PloS one.

Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System

D. Durden, Shweta Joshi, 2019, Journal of oncology.

Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions

Shweta Joshi, 2020, Cancers.

Chapter 10 Novel Therapeutic Approaches for Neuroblastoma

D. Durden, Shweta Joshi, A. Singh, 2017 .

De novo variants in population constrained fetal brain enhancers and intellectual disability

D. Fitzpatrick, Inês Cebola, J. Ferrer, 2019, bioRxiv.

Rac2 Controls Tumor Growth, Metastasis and M1-M2 Macrophage Differentiation In Vivo

T. Ideker, Janusz Dutkowski, D. Durden, 2014, PloS one.

Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis

D. Durden, J. Garlich, T. Kutateladze, 2017, Proceedings of the National Academy of Sciences.

Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

P. Tamayo, C. Glass, D. Durden, 2020, Molecular Cancer Therapeutics.

A PKC-SHP1 signaling axis desensitizes Fcγ receptor signaling by reducing the tyrosine phosphorylation of CBL and regulates FcγR mediated phagocytosis

D. Durden, Shweta Joshi, A. Singh, 2014, BMC Immunology.

Rare association of postmenopausal uterine lipoleiomyoma in a frail woman with deranged lipid profile

B. Warpe, Shweta Joshi, 2016 .

BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma

P. Tamayo, A. Yu, Shweta Joshi, 2021, Cancers.

Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma

D. Rohila, Alice Yu, A. Sharabi, 2023, Frontiers in Immunology.

Bone Marrow Aspiration and Bone Marrow Biopsy in Hematological Disorders

Shweta Joshi, J. Wader, Sujatha Kanethkar, 2020 .

PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression

S. Kesari, D. Durden, M. Makale, 2013, Journal of Neuro-Oncology.

Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma

A. Lowy, D. Rohila, Tatiana Hurtado de Mendoza, 2023, Cancer research.

Leukemoid reaction in sarcomatoid type of renal cell carcinoma (SRCC): a rare case report

B. Warpe, Shweta Joshi, 2016 .

A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis

D. Durden, Shweta Joshi, A. Singh, 2014, Molecular Cancer Research.

De novo mutations in fetal brain specific enhancers play a significant role in severe intellectual disability

Madapura M. Pradeepa, Shweta Joshi, M. Garstang, 2019 .

The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma

D. Durden, T. Kutateladze, Guillermo A. Morales, 2021, iScience.

Trends in Pharmacogenetics

Shweta Joshi, P. HusaynAhmed, 2018 .

New insights into SYK targeting in solid tumors.

Shweta Joshi, 2024, Trends in pharmacological sciences.